Dr. Jonathan Ostrow
Dr. Jonathan Ostrow (Emeritus member)
After completing Medical School at Albert Einstein College of Medicine in NYC in 1962, and Internship at the University of California Medical Center in San Francisco, in 1963, Dr Ostrow served for two years in the US Army Medical Corps, as the Post Preventive Medicine (public health) Officer, Aberdeen Proving Ground, MD, where he first encountered the problem of tuberculosis as a public health problem.
After completing his
military service, Dr Ostrow
family moved to Seattle for his
Internal Medicine Residency at the University of Washington
, which he
completed between 1965-68.
He then joined the Medical Staff at Firland (tuberculosis) Hospital, where he remained for the next five years, and became it's final Medical Director.
actively participated in the rapidly changing methods of treatment for tuberculosis, which allowed for much shorter hospitalizations for TB as better drugs became available, and eventually led to the closing of Firland
While at Firland
, Dr Ostrow
participated in the various multi-hospital TB therapy trials sponsored by the Tuberculosis Section of the US Public Health Service Center for Disease Control
, which culminated in the FDA approval of Rifampin, the last major TB drug to become available for many years.
While acting as Firland's Medical Director in the early 1970s, Dr Ostrow first became a member of the Firland Sheltered Workshop Board of Directors.
When the Hospital closed in 1973, the Board decided to continue the Workshop operations, and open it to all disabled workers, rather than just to TB patients.
From this decision evolved the current Firland Foundation
Workshop, which moved into new quarters in the 1990s, and has maintained both a mutually beneficial working relationship with the Boeing Company
, and other local employers, and also preserved it's mission as a supporter of research and advocacy for the care of tuberculosis in Washington State.
fter Firland's closure in 1973, Dr Ostrow entered private practice in Seattle until retiring in 2002, and has maintained his interest in tuberculosis care, He remains a Clinical Professor of Medicine at the University of Washington, and is a member of the Washington State Tuberculosis Advisory Council.
has become the longest serving member of the Firland Foundation
Board, having maintained membership continuously since 1972.